The diagnostic category of amnesia associated with mild cognitive impairment (MCI) attempts to describe those people who have memory loss but relatively preserved abilities in other cognitive areas so as not to merit a diagnosis of dementia. The importance of this group of people is that they represent a population at high risk of developing dementia, especially Alzheimer's disease, and are an appropriate target for early diagnosis and intervention strategies. Accordingly, the major goal of this proposal is to determine whether sensitive behavioral tasks together with eye-tracking technology will reveal a profile of performance in MCI patients that is useful in predicting the onset of Alzheimer's Disease or other dementias. The overall plan is to test a minimum of 60 MCI patients and 60 matched normal control (NC) subjects (recruited from the Clinical Core) initially and on yearly follow-up sessions on two declarative memory tasks and one nondeclarative memory task, together with eye-tracking. We have good experience with all of the tasks and with eye-tracking, and we have successfully administered the preferential looking task together with eye-tracking in pilot work with MCI, PD, and NC subjects. A group of 30 patients with Alzheimer's Disease (AD) and a group of 30 Parkinson's Disease patients without dementia (PD) also will be tested (these groups will also be recruited from the Clinical Core). The performance of the AD and PD groups and the NC group will provide important points of comparison with the performance of the MCI patients initially and at follow-up sessions. The PD group also serves as a critical control group for the MCI and AD patients. Specifically, PD patients, like the AD patients, have neurologic damage, but unlike AD patients, the PD patients don't have dementia. An important contribution from this work would be the ability to diagnose sooner than is now possible in MCI patients oncoming cognitive decline, at a time when the nervous system is less compromised and, accordingly, more likely to benefit from therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG025688-02
Application #
7309920
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2006-05-01
Budget End
2007-04-30
Support Year
2
Fiscal Year
2006
Total Cost
$114,254
Indirect Cost
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Johnson, Erik C B; Dammer, Eric B; Duong, Duc M et al. (2018) Deep proteomic network analysis of Alzheimer's disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease. Mol Neurodegener 13:52
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
An, Yang; Varma, Vijay R; Varma, Sudhir et al. (2018) Evidence for brain glucose dysregulation in Alzheimer's disease. Alzheimers Dement 14:318-329
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826
Chandramowlishwaran, Pavithra; Sun, Meng; Casey, Kristin L et al. (2018) Mammalian amyloidogenic proteins promote prion nucleation in yeast. J Biol Chem 293:3436-3450
Bai, Yushi; Chotera, Agata; Taran, Olga et al. (2018) Achieving biopolymer synergy in systems chemistry. Chem Soc Rev 47:5444-5456
Chou, Ching-Chieh; Zhang, Yi; Umoh, Mfon E et al. (2018) TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat Neurosci 21:228-239

Showing the most recent 10 out of 444 publications